导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 15.18% | 577/4773 |
| 近一周 | -3.88% | 5064/5467 |
| 近一月 | -2.23% | 882/5421 |
| 近一季 | 4.46% | 422/5238 |
| 近半年 | -4.65% | 2984/4931 |
| 近一年 | 24.09% | 307/4400 |
| 近两年 | 31.94% | 2183/2954 |
| 近三年 | 31.31% | 1024/2253 |
| 成立以来 | 83.73% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
17.35% 36/4961 |
-14.48% 4577/5312 |
- - |
- - |
| 2025 | 2.97% 3154/4813 |
-10.85% 3441/3635 |
0.73% 2578/4076 |
3.91% 3713/4524 |
10.36% 184/4813 |
| 2024 | 13.43% 1139/3463 |
16.78% 2/2808 |
3.48% 269/3014 |
1.63% 2951/3129 |
-7.64% 2783/3463 |
| 2023 | 18.41% 24/2656 |
9.02% 430/2280 |
1.24% 229/2385 |
8.85% 13/2515 |
-1.43% 326/2655 |
| 2022 | 16.93% 1/2207 |
15.94% 9/1919 |
8.46% 362/2016 |
7.93% 1/2113 |
-13.84% 2072/2208 |
| 2021 | 40.21% 32/1822 |
7.28% 76/1255 |
11.84% 359/1330 |
32.57% 11/1466 |
-11.85% 1616/1822 |
| 2020 | -9.35% 990/1250 |
-19.27% 1007/1028 |
-2.35% 1036/1067 |
6.90% 814/1164 |
7.56% 706/1184 |
| 2019 | 11.67% 726/1092 |
18.94% 637/754 |
-3.84% 412/804 |
-5.34% 791/850 |
3.15% 845/918 |
| 2018 | -24.34% 322/834 |
- - |
- - |
- - |
-21.35% 671/691 |
| 2017 | 4.75% 381/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.57% 264/605 |
- - |
- - |
- - |
- - |
| 2015 | -17.98% 299/575 |
- - |
- - |
- - |
- - |
| 2014 | 21.35% 189/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证能源ETF VS. 长安沪深300非周期A(740101) |